RxDoctor Payments Data

Kate Muramoto, OD

Optometrist · Beverly Hills, CANPI 1316618481

Payments from drug & device makers

$3,653in general payments, 2019–2025

Across 48 payments — averaging $76.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$3K
  • Sun Pharmaceutical Industries Inc.$311
  • Oyster Point Pharma, Inc.$210
  • Glaukos Corporation$153
  • Dompe US, Inc.$136
  • Coopervision Inc.$113
  • plus $106 from 4 others

What the payments were for

  • Travel & lodging$1,40138%
  • Food & beverage$2,23361%
  • Education$90%
  • Gifts$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,653 in reported general payments places this provider in the 90th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$58,345
Medicare patients
285
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast88$72,004
RestasisCyclosporine78$67,229
Restasis MultidoseCyclosporine36$23,257
CequaCyclosporine12$15,738
Cyclosporine47$14,521
LumiganBimatoprost14$7,625
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$4,031
Latanoprost225$2,168
Brimonidine Tartrate30$1,460
Azelastine Hcl41$852
Prednisolone Acetate19$742
ErythromycinErythromycin Base50$671
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$399
Timolol Maleate52$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Lumigan$15$98,110128 claims
Bausch & Lomb Americas Inc.Xiidra$2,623$72,00488 claims
Sun Pharmaceutical Industries Inc.Cequa$311$15,73812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,778 optometrist providers in California.

Other optometrist in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →